Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZZ) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Core Scientific (CORZZ) over the last 5 years, with Q3 2025 value amounting to -$5.3 million.

  • Core Scientific's Cash from Financing Activities fell 10292.17% to -$5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $556.9 million, marking a year-over-year increase of 17418.99%. This contributed to the annual value of $819.6 million for FY2024, which is 193557.75% up from last year.
  • As of Q3 2025, Core Scientific's Cash from Financing Activities stood at -$5.3 million, which was down 10292.17% from -$31.8 million recorded in Q2 2025.
  • Over the past 5 years, Core Scientific's Cash from Financing Activities peaked at $598.2 million during Q4 2024, and registered a low of -$45.1 million during Q3 2022.
  • Moreover, its 5-year median value for Cash from Financing Activities was $21.0 million (2021), whereas its average is $86.5 million.
  • As far as peak fluctuations go, Core Scientific's Cash from Financing Activities tumbled by 14804.0% in 2023, and later surged by 542448.58% in 2024.
  • Core Scientific's Cash from Financing Activities (Quarter) stood at $170.2 million in 2021, then plummeted by 77.63% to $38.1 million in 2022, then tumbled by 148.04% to -$18.3 million in 2023, then surged by 3369.23% to $598.2 million in 2024, then crashed by 100.89% to -$5.3 million in 2025.
  • Its Cash from Financing Activities stands at -$5.3 million for Q3 2025, versus -$31.8 million for Q2 2025 and -$4.2 million for Q1 2025.